Effects of aldose reductase inhibitor on exercise capacity in diabetic cardiomyopathy
James Januzzi, MD
Increasing the use of SGLT2i and GLP-1RA with a remote program in T2D and high CV or kidney risk
Alexander J. Blood, MD
Antoni Bayés-Genís, MD, PhD
Patrick Rossignol, MD, PhD
Aaron Wong, MD
Loading...
We’re glad to see you’re enjoying PACE-CME… but how about a more personalized experience?
Press cancel to remain on PACE-CME. Press the link below or the continue button to keep going.